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Objectives: Rapid influenza tests are increasingly used in surveillance systems and for clinical
care in Southeast Asia. However, the performance and utility of rapid influenza tests under field
conditions in rural Southeast Asia has not been evaluated.
Methods: In the context of a larger study on the causes of respiratory illness in rural Thailand, we
used a rapid test to collect data on influenza burden, seasonality, and cost of illness. We compared
the performance of the QuickVue1 Influenza Test to tissue cell viral culture and reverse
transcriptase-polymerase chain reaction (RT-PCR) among 1092 Thai patients meeting the World
Health Organization case definition for influenza-like illness over a 12-month period.
Results: The sensitivity and specificity of the QuickVue test compared to viral culture were 77%
and 96%, respectively. Rapid influenza tests were useful to describe the seasonality of influenza,
estimate the cost of illness, increase the sensitivity of surveillance, conduct outbreak responses,
and guide evaluation of suspected avian influenza virus infections.
Conclusions: Despite their high cost, rapid influenza diagnostic tests are useful tools for influenza
research, surveillance, and outbreak investigations in Southeast Asia.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.* Corresponding author. Tel.: +84 4 943 3738; fax: +84 4 943 3740.
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In developed countries in temperate climates, influenza is an
important cause of morbidity among healthy children and
adults and of mortality among the very young, the elderly,
and those with chronic illnesses during seasonal influenzaSociety for Infectious Diseases.
Performance of rapid influenza tests 167epidemics.1—3 In developed economies, influenza may cause
10—12% of all sickness absence resulting in significant direct
medical costs and lost wages.4,5 Much less is known about the
disease burden, seasonality, and cost of influenza in tropical
countries. Improving the sensitivity of influenza surveillance
and documenting the burden of disease in Southeast Asia is a
World Health Organization (WHO) priority.6 Virological sur-
veillance is conducted by performing cell culture on respira-
tory specimens from patients with influenza-like illness (ILI).
While viral culture yields isolates needed for surveillance and
vaccine strain selection, results are not timely, the process is
labor-intensive, and requires specialized laboratory skills.7
In recent years commercially available rapid influenza
diagnostic tests have become available in developed coun-
tries. Rapid tests are primarily used in clinical settings where
prompt testing can influence treatment decisions.8—10 In
addition, France, Switzerland, and the USA States of Hawaii
and Colorado have experimented with integrating rapid tests
into their influenza surveillance systems.11—13 The high spe-
cificity and the improved speed in reporting with rapid tests
can improve the early warning capacity of some influenza
surveillance systems.14 In controlled laboratory trials and in
medical practices, rapid influenza tests have generally
demonstrated moderate sensitivity (45—90%) and good spe-
cificity (86—100%) to detect influenza virus infection.8,15
There has been considerably less experience with rapid
influenza tests in Southeast Asia. Use of rapid tests has been
limited by factors including high cost (US $7—12/test), lim-
ited availability, few available treatment options for influ-
enza, and concern about the performance of rapid tests in
the hot and humid field conditions found in rural tropical
medical clinics.
To evaluate the utility and performance of rapid tests for
influenza research, surveillance, and outbreak response, we
employed a commercially available rapid test during a one-
year period in a field setting as one component of an influenza
research study in Thailand.
Materials
We used the QuickVue1 Influenza Test, which detects influ-
enza antigens in clinical specimens and provides results in
10 min. This test is a lateral-flow immunoassay that uses
monoclonal antibodies specific for influenza viral nucleopro-
tein antigens and detects both influenza A and B, but does not
distinguish between them. The test uses an extraction
reagent to disrupt virus particles in the clinical specimen.
Viral nucleoproteins are subsequently exposed and react with
an antibody-coated strip. If influenza virus is present, a pink-
to-red test line along with a blue procedural control line will
appear on the test strip.
Methods
This research was carried out with the approval of, and in
compliance with the standards of, the ethical review com-
mittees of the United States Centers for Disease Control and
Prevention, the Thailand Ministry of Public Health, and the
Tulane University School of Public Health.
We enrolled patients of all ages during a 12-month period
from September 1, 2003 to August 31, 2004. Patients thatmetthe WHO ILI clinical case definition of a fever greater than
38 8C with either cough or sore throat and no alternative
diagnosis were enrolled during two clinic days per week at
five of eight hospital outpatient clinics in Sa Kaeo province of
rural eastern Thailand.16 The province shares a border with
Cambodia, a 2003 population of 438 557, and an average
annual household income of US $248.17 The province has
seven public hospitals, a single military hospital, and no
private hospitals. Sa Kaeo is the site of an active, popula-
tion-based pneumonia surveillance system carried out
through collaboration between the Thailand Ministry of Pub-
lic Health (MOPH) and the US Centers for Disease Control and
Prevention (CDC).18
Patients with ILI who presented to the outpatient depart-
ment were asked to enroll in the study. After obtaining signed
consent, the swab provided in the test kit was used to collect
a nasal specimen and the QuickVue rapid test was performed
according to the manufacturer’s instructions by one of three
research nurses trained by the Thailand National Institute of
Health (NIH) influenza laboratory. The research nurses were
asked to evaluate the ease of use and durability of the rapid
test during the one-year study period. The results of the test
were promptly reported to both the patient and the physi-
cian. Summary reports of the number and proportion of
positive rapid influenza tests were submitted weekly to
strengthen the national influenza surveillance system.
Nasopharyngeal samples were also collected from all
patients using a Dacron swab, inserted into 3% nutrient broth
viral transport media and placed on wet ice. Specimens were
then refrigerated for less than 48 h at 2—8 8C until trans-
ported to the provincial hospital for aliquoting and storage at
70 8C. Once weekly, specimens were transported on dry ice
to the Thai NIH laboratory in Bangkok for viral culture in
Madin—Darby canine kidney cells (MDCK) and human epithe-
lial (HEp-2) cells using established procedures. Specimens
were centrifuged at 4500 rpm for 20 min and 0.1 mL of each
supernatant was inoculated onto confluent monolayers of
MDCK and HEp-2 cells. MDCK cells were maintained in mini-
mal essential medium (MEM) supplemented with 0.2% BSA
and 0.2 mg/mL TPCK—trypsin, and HEp-2 cells were main-
tained in MEMwith 2% FBS. Both cells were incubated at 35 8C
for 7—10 days and observed daily for cytopathic effect (CPE).
If a sample showed CPE, it was further tested by immuno-
fluorescence assay (IFA) using a commercial respiratory virus
monoclonal antibody panel to detect influenza A and B,
parainfluenza viruses types 1, 2, and 3, respiratory syncytial
virus, and adenovirus (Chemicon Cat. No. 3105). Cultures not
showing CPE were passaged once using harvested scraped
cells and fluid as inoculum and observed for CPE. Both CPE
negative and positive samples were confirmed by IFA.19
For reverse transcriptase-polymerase chain reaction (RT-
PCR) testing, specimens were added to lysis buffer AL (QIA-
GEN Inc., Valencia, CA, USA) and held at70 8C until shipping
to CDC on dry ice. Total nucleic acid was extracted using the
QIAamp1 Virus BioRobot MDx kit (QIAGEN) following manu-
facturer’s instructions. An RT-PCR assay panel consisting of
respiratory syncytial virus, human parainfluenza viruses 1, 2,
and 3, human metapneumovirus, influenza viruses A and B,
adenovirus, and picornavirus was performed as previously
described,20 but with the following modifications: the sense-
strand primers of each set were 50-end-labeled with the
fluorescent dye, Cy5, and amplicons were analyzed using
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Pos Pos Pos 151
Neg Neg Neg 823
Pos Neg Pos 28
Pos Pos Neg 7
Pos Neg Neg 6
Neg Pos Neg 4
Neg Pos Pos 43
Neg Neg Pos 30the CEQTM 8000 Genetic Analysis System (Beckman Coulter,
Fullerton, CA, USA). All assays were run with standardized
viral nucleic acid extracts and nuclease-free water for posi-
tive and negative controls, respectively, and all samples were
tested by RT-PCR for the human GAPDH enzyme to ensure
adequate recovery of sample RNA and absence of RT-PCR
inhibitors.
Demographic and risk factor data were collected at the
time of enrollment. Patients who were positive for influenza
with the rapid test were then given a cost diary to facilitate
the recording of healthcare utilization and household costs
associated with the illness. Three weeks after enrollment,
each patient with a positive rapid influenza test was inter-
viewed by a research nurse to collect cost of illness data
based on the cost diary.
In 2003, to prepare for use of the rapid test during out-
break investigations, Thai and US epidemiologists received
training to conduct the rapid test according to the manu-
facturer’s guidelines. During early 2004 when cases of human
H5N1 infection were reported in Thailand, several hundred
laboratory staff and nursing personnel in MOPH hospitals also
received training from scientists at the Thailand National
Influenza Center. Rapid tests were then distributed to MOPH
facilities across Thailand for use with patients suspected of
having avian influenza H5N1 infection.
Data were analyzed using SPSS 12.0 (SPSS Inc, Chicago,
Illinois, USA) and EpiInfo 6.0 (US CDC, January 2001) statis-
tical software. The Chi-square test was used to compare
proportions and a p value of <0.05 was considered signifi-
cant.
Results
We enrolled 1092 patients (age range 1 month—86 years;
median 35 years) of whom 587 (54%) were less than six years
of age. Five hundred and fifty-seven (51%) enrolled patients
were male. Four hundred and nineteen patients (38%) and
988 (90%) of specimens were collected within two and four
days of the onset of symptoms, respectively.
One hundred and ninety-two of 1092 (18%) rapid tests
were positive using the QuickVue test while viral culture
indicated that 205 of 1092 (19%) were positive for influenza.
Of these isolates 178 (87%) and 27 (13%) were influenza type A
and type B viruses, respectively. No cases of avian influenza A
(H5N1) infection were identified.
When compared to cell culture, the QuickVue influenza
test produced 34 false positive and 47 false negative resultsFigure 1 Proportion of rapid test influenza positwith a sensitivity and specificity of 77% and 96%, respectively.
Of the 34 specimens that were positive by rapid test but
negative by viral culture, 28 (82%) were RT-PCR positive. Of
the 47 results that were negative by rapid test but positive by
cell culture, RT-PCR was positive in only four (9%) cases
(Table 1). There was substantial agreement between the
rapid test and both cell culture and RT-PCR (Kappa 0.751
and 0.758, respectively) and almost perfect agreement
between cell culture and RT-PCR methods (Kappa 0.810).21
The proportion of rapid tests positive for influenza was
highest during the months of June—August (Figure 1). Over
the 12-month study period, the QuickVue test had a positive
predictive value (PPV) of 82% and a negative predictive value
(NPV) of 95%. Three hundred and eighty-two patients were
enrolled during the months of June through August and 127
(33%) of these patients tested influenza positive by cell
culture. During this three-month period of highest influenza
activity, the PPV of the rapid test increased to 88% while the
NPV decreased to 90% (Table 2).
All nasopharyngeal specimens were tested using RT-PCR
methods and 252 (23%) of these specimens were influenza
positive. Tissue cell culture identified influenza in 205 (81%)
of these specimens and was significantly less sensitive than
RT-PCR ( p < 0.0001). When the rapid test results were com-
pared to RT-PCR testing on these specimens, the QuickVue
test had a lower sensitivity of 71% ( p = 0.144) and an
increased specificity (98%) ( p = 0.019) than when the test
was compared to tissue cell culture. In children less than six
years of age, the QuickVue test agreed with the cell culture
result in 57 of 70 (81%) cases while the test identified 101 of
135 (75%) of culture positive patients aged 18 years or older
( p = 0.28). The QuickVue test was not more likely to indicate
a positive result when viral culture was positive for influenzaive outpatient specimens by month (n = 1092).
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Table 2 Performance of the QuickVue1 Influenza Test compared to viral cell culture
Time period Specimens (n, % positive) Sensitivity (%) Specificity (%) PPV (%) p valuea NPV (%) p valuea
12 months 1092 (192, 18) 77 96 82 95
Lowest prevalence
(September—May)
710 (78, 11) 77 96 73 97
Highest prevalence
(June—August)
382 (114, 30) 77 96 88 (0.009) 90 (0.00001)
a Comparison of PPV and NPV during highest and lowest influenza prevalence periods. PPV, positive predictive value; NPV, negative
predictive value.type B virus 22/27 (82%) than when compared to influenza
type A 136/178 (76%) ( p = 0.51).
In July 2003, an outbreak of febrile respiratory illness was
reported in a remote boarding school for hill tribe children in
the mountains of northern Thailand. For the first time in
Thailand, a team equipped with rapid influenza tests was
dispatched to conduct an epidemiological investigation. Nine
of 19 (47%) of nasal swabs collected from acutely ill children
tested positive for influenza virus, later confirmed by tissue
cell culture as influenza A/Fujian/411/2002 H3N2.22
Discussion
We chose to evaluate the QuickVue test because prior experi-
ence in the USA suggested it was a simple and durable test
that might be useful in the more rigorous environments found
in rural Thai clinics. We hypothesized that the extremes of
heat and humidity and the variability in specimen collection,
handling, and testing common to field settings might nega-
tively impact the performance of the rapid test when com-
pared to laboratory evaluations conducted in developed
countries. However, we found that under field conditions
in rural Thai clinics, the QuickVue Influenza Test had a
sensitivity and specificity compared to viral culture of 77%
and 96%, respectively. This compares favorably with findings
from laboratory evaluation studies in Canada, the USA, and
Japan, where the test yielded a median sensitivity of 79.2%
(range 74—95%) and a median specificity of 91.9% (range 76—
98%).25—27 During our study year, influenza infection demon-
strated marked seasonal variation. Positive rapid test results
were significantly more likely to be confirmed by cell culture
(true positive) during the seasonal peak of influenza activity
while false positives were more likely to occur in low pre-
valence months. Overall, the positive and negative predic-
tive values of the test were 82% and 95%, respectively.
Consistent with other studies, we found that RT-PCR was a
more sensitive method to identify influenza virus infection
than tissue cell culture.23,24 The rapid test yielded 34 false
positive specimens and 47 false negative results when com-
pared to cell culture, but in the majority of these cases RT-
PCR testing agreed with the rapid test. This is probably due to
the significant reduction in the recovery of influenza viruses
caused by transport delays in the inoculation of samples into
cell culture and the deleterious effects of the freeze—thaw
cycle. These data suggest that RT-PCR could be considered
the new gold standard, especially for specimens that must be
frozen and shipped.
Children with influenza infections may experience higher
viral loads and shed virus longer than adults. Thus, somerapid tests have demonstrated increased sensitivity in
younger age groups.15,23,28 In this study, the rapid test was
not more sensitive in children under six years of age when
compared to adults aged 18 years and older. Some studies
indicate that rapid tests may be less sensitive for influenza
type B virus than for influenza type A.29,30 This may be due to
lower viral loads during infection with influenza virus type B
than with influenza type A.31,32 The QuickVue test was
equally sensitive in detecting infection with both influenza
type A and type B viruses. Our experience in this study
afforded insight into several potential new uses for rapid
influenza testing in developing countries.
Uncomplicated viral respiratory infections can represent a
significant economic burden to poor families as a result of lost
work, costs of transportation to medical clinics, and out-of
pocket treatment costs.33 To minimize recall and misclassi-
fication bias, patients must be correctly diagnosed and inter-
viewed early in the course of illness. However, clinical
diagnosis of influenza is unreliable and obtaining viral cell
culture results can take several weeks.34,35 Use of the Quick-
Vue test allowed us to effectively identify symptomatic
influenza patients in the outpatient department who were
later interviewed to collect cost of illness data (reported
elsewhere).
An improved understanding of influenza seasonality in
Thailand and early identification of seasonal epidemics will
allow for more effective timing of vaccination and for
improved clinical management. Our daily use of rapid influ-
enza tests in outpatient clinics functioned as a sensitive,
active surveillance system. Real-time knowledge of the pro-
portion of ILI patients who were influenza positive provided
unprecedented insight into the level of circulating human
influenza viruses during 2003—4 and contributed valuable
new information on the seasonality of influenza in Thailand.
The July 2003 outbreak of febrile respiratory illness in a
boarding school in the mountains of northern Thailand was
the first use of rapid influenza tests for an epidemiologic
investigation in Thailand. Rapid influenza tests enabled
investigators to promptly identify influenza as the cause of
the outbreak. Immediate identification of the etiology of the
outbreak facilitated treatment decisions by local clinicians,
guided control measures such as cohorting, quarantine, and
school closure. Thailand MOPH epidemiological response
teams are now routinely supplied with rapid influenza tests
when investigating respiratory illness outbreaks.
During 2004, East and Southeast Asia experienced an
outbreak of avian influenza H5N1 that resulted in more than
100 million dead or culled poultry, and 44 human cases with
32 deaths in Thailand and Vietnam.36 Reassortment of the
H5N1 avian virus with circulating human influenza A viruses
170 J.M. Simmerman et al.









Missed isolates Efficiency %
(n isolates/n cultured)
Culture all specimens 1092 0 1092 205 0 19 (205/1092)
Culture only rapid test
positive specimens
1092 1092 192 158 47 82 (158/192)
a Assumes rapid test sensitivity of 77%, specificity of 96%, and 19% culture positive. ILI, influenza-like illness.could generate a novel strain that would cause a global
influenza pandemic.37,38 The Thailand MOPH incorporated
rapid influenza testing into its diagnosis and treatment algo-
rithm and distributed 59 200 rapid influenza tests to 904
hospitals and public health offices across the country. Briefly,
if the rapid test result was negative in patients with clinical
features incompatible with H5N1 infection and without a
clear history of poultry exposure, specimens were generally
not forwarded to central laboratories for viral culture. If the
rapid test returned positive, additional expedited testing was
conducted to distinguish between infection with H5N1 and
human influenza A virus. The results of these rapid tests were
not systematically recorded and although they were consid-
ered to be a useful tool in the outbreak response, there are no
published studies on the accuracy of rapid tests to detect
human avian influenza infection. Therefore, clinical manage-
ment decisions should be guided by specific H5N1 testing
algorithms with close attention to exposure history and
clinical presentation.39 The pandemic threat of H5N1 avian
influenza virus underscores the importance of maintaining a
sensitive human influenza surveillance system.
The WHO Influenza Surveillance Network consists of 112
National Influenza Centers (NIC) in 83 countries and four
collaborating centers worldwide.16 The network functions
as a global virologic surveillance system that collects influ-
enza isolates for strain surveillance, pandemic preparedness,
and annual vaccine composition decisions. For NICs in devel-
oping countries, equipping and staffing complex laboratories
needed to characterize influenza viruses is challenging. Con-
sidering the high costs and limited resources, approaches to
maximizing efficiency and increasing the number of isolates
submitted to the WHO network merits attention. For physi-
cians, access to rapid influenza tests is appealing to improve
clinical care and may serve as an incentive to submit speci-
mens.9,12 The application of rapid testing could allow influ-
enza laboratories to focus efforts on clinical specimens that
are most likely to yield influenza isolates, thereby increasing
efficiency and possibly reducing costs. While conducting viral
cell culture on all specimens is ideal, using rapid tests as a
screening tool for influenza surveillance could strengthen
overall virological surveillance (Table 3).
In summary, the rapid influenza test demonstrated mod-
erate sensitivity and high specificity under field conditions in
rural Thailand. The research nurses reported that the test
was easy to perform, simple to interpret, and the test kit
materials were durable in field conditions. The rapid test
demonstrated utility in a variety of roles including collecting
cost-of-illness data, conducting investigations of human
influenza outbreaks, and responding to the avian influenza
A/H5N1 outbreak. While their high cost per test currently
limits the large-scale application of rapid influenza tests in
resource-poor countries, growing market competition amongmanufacturers may decrease costs and increase availability
in the future. Further evaluation is needed to determine if
integrating rapid influenza tests can improve the perfor-
mance of national influenza surveillance systems in Southeast
Asia.
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